Clinical superinfection in complicated urinary tract infections: therapy with broad-spectrum beta-lactam antibiotics in urology.
In Japan, new antibiotics under development are compared with conventional antibiotics in Phase III controlled studies. Since the patients' demographic data, dosage, treatment period, etc. are made as uniform as possible in these studies, the results obtained are suitable for evaluating the characteristics of the new antibiotics. Most patients developing clinical superinfections suffer from complicated urinary tract infections due to underlying diseases. In order to avoid clinical superinfections, clinicians have to try to eradicate or alleviate these underlying diseases. The predominant microorganisms that may cause clinical superinfections to develop following therapy with broad-spectrum beta-lactam antibiotics include enterococci, Pseudomonas aeruginosa, other Pseudomonas spp. and fungi. Enterococci may frequently be detected in patients with mixed infections and can easily be dealt with by changing the antibiotics.
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001419:Bacteria / Q000302:isolation & purification; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002439:Cefotaxime / Q000009:adverse effects; D002986:Clinical Trials as Topic; D006801:Humans; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D002439:Cefotaxime